Real-World Trends in the Evaluation of Medical Products

被引:2
作者
Hennessy, Sean [1 ,2 ,3 ]
Berlin, Jesse A. [4 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Ctr Real World Effectiveness & Safety Therapeut, Philadelphia, PA 19104 USA
[3] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[4] Rutgers State Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, New Brunswick, NJ USA
关键词
effectiveness; pharmacoepidemiology; real-world evidence; research methods; safety; DRUG; SCORE;
D O I
10.1093/aje/kwac172
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
There is a compelling need to evaluate the real-world health effects of medical products outside of tightly controlled preapproval clinical trials. This is done through pharmacoepidemiology, which is the study of the health effects of medical products (including drugs, biologicals, and medical devices and diagnostics) in populations, often using nonrandomized designs. Recent developments in pharmacoepidemiology span changes in the focus of research questions, research designs, data used, and statistical analysis methods. Developments in these areas are thought to improve the value of the evidence produced by such studies, and are prompting greater use of real-world evidence to inform clinical, regulatory, and reimbursement decisions.
引用
收藏
页码:1 / 5
页数:5
相关论文
共 43 条
  • [1] Pediatric Aspects of Inpatient Health Information Technology Systems
    不详
    [J]. PEDIATRICS, 2008, 122 (06) : E1287 - E1296
  • [2] Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
    Austin, Peter C.
    Stuart, Elizabeth A.
    [J]. STATISTICS IN MEDICINE, 2015, 34 (28) : 3661 - 3679
  • [3] A history of pharmacoepidemiology
    Begaud, Bernard
    [J]. THERAPIE, 2019, 74 (02): : 175 - 179
  • [4] The Magic of Randomization versus the Myth of Real-World Evidence
    Collins, Rory
    Bowman, Louise
    Landray, Martin
    Peto, Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07) : 674 - 678
  • [5] Long-Term Association of Air Pollution and Hospital Admissions Among Medicare Participants Using a Doubly Robust Additive Model
    Danesh Yazdi, Mahdieh
    Wang, Yan
    Di, Qian
    Wei, Yaguang
    Requia, Weeberb J.
    Shi, Liuhua
    Sabath, Matthew Benjamin
    Dominici, Francesca
    Coull, Brent A.
    Evans, John S.
    Koutrakis, Petros
    Schwartz, Joel D.
    [J]. CIRCULATION, 2021, 143 (16) : 1584 - 1596
  • [6] A National Assessment of Medication Adherence to Statins by the Racial Composition of Neighborhoods
    Davis, Andrew M.
    Taitel, Michael S.
    Jiang, Jenny
    Qato, Dima M.
    Peek, Monica E.
    Chou, Chia-Hung
    Huang, Elbert S.
    [J]. JOURNAL OF RACIAL AND ETHNIC HEALTH DISPARITIES, 2017, 4 (03) : 462 - 471
  • [7] Broadening the reach of the FDA Sentinel system: A roadmap for integrating electronic health record data in a causal analysis framework
    Desai, Rishi J.
    Matheny, Michael E.
    Johnson, Kevin
    Marsolo, Keith
    Curtis, Lesley H.
    Nelson, Jennifer C.
    Heagerty, Patrick J.
    Maro, Judith
    Brown, Jeffery
    Toh, Sengwee
    Nguyen, Michael
    Ball, Robert
    Pan, Gerald Dal
    Wang, Shirley V.
    Gagne, Joshua J.
    Schneeweiss, Sebastian
    [J]. NPJ DIGITAL MEDICINE, 2021, 4 (01)
  • [8] Creating a Common Data Model for Comparative Effectiveness with the Observational Medical Outcomes Partnership
    FitzHenry, F.
    Resnic, F. S.
    Robbins, S. L.
    Denton, J.
    Nookala, L.
    Meeker, D.
    Ohno-Machado, L.
    Matheny, M. E.
    [J]. APPLIED CLINICAL INFORMATICS, 2015, 6 (03): : 536 - 547
  • [9] Food and Drug Law Institute, FDAS HIST US REAL WO
  • [10] Common Models, Different Approaches
    Gagne, Joshua J.
    [J]. DRUG SAFETY, 2015, 38 (08) : 683 - 686